Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Cells in the body have to move around in order to do their jobs. During development, for instance, cells are distributed to ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

A bill that would ban the use of mRNA vaccines, including for Covid-19, is on its way to the House floor after passing out of ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Friday reported a loss of $1.12 billion in its fourth quarter. On a per-share basis, the Cambridge, Massachusetts-based company ...

Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday.

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...